Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline o...

Descripción completa

Detalles Bibliográficos
Autores principales: Paules, Catharine I, Gallagher, Shannon K, Rapaka, Rekha R, Davey, Richard T, Doernberg, Sarah B, Grossberg, Robert, Hynes, Noreen A, Ponce, Philip O, Short, William R, Voell, Jocelyn, Wang, Jing, Yang, Otto O, Wolfe, Cameron R, Lye, David C, Dodd, Lori E, Benson, Constance A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436376/
https://www.ncbi.nlm.nih.gov/pubmed/34379740
http://dx.doi.org/10.1093/cid/ciab695
Descripción
Sumario:This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.

Ejemplares similares